# AstraZeneca PLC Imfinzi significantly improves overall survival in the Phase III trial

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-imfinzi-significantly-improves-overall-survival-phase-iii-trial/412751704
- Published: 2018-05-25T07:52:09+01:00
- Author: Giles Arbor

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
LONAZN) and MedImmune, its global biologics research and development arm, today 
announced positive overall survival (OS) results for the Phase III PACIFIC trial,
a randomised, double-blinded, placebo-controlled, multi-centre trial of Imfinzi (
durvalumab) in patients with unresectable Stage III non-small cell lung cancer (
NSCLC) whose disease had not progressed following platinum-based chemotherapy concurrent
with radiation therapy (CRT).

A planned interim analysis conducted by an Independent Data Monitoring Committee
concluded that the trial has met its second of two primary endpoints by showing 
statistically-significant OS benefit with clinically-meaningful improvement in patients
receiving Imfinzi compared to placebo. The safety and tolerability profile for Imfinzi
was consistent with that reported at the time of the progression-free survival (
PFS) analysis. AstraZeneca plans to present results from the PACIFIC trial at a 
forthcoming medical meeting.

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical
Officer at AstraZeneca, said: “The readout of positive overall survival data at 
the interim analysis of the PACIFIC trial provides additional compelling evidence
of the clinical benefit that Imfinzi can offer patients in this earlier stage of
lung cancer. We look forward to sharing these results with Health Authorities to
support ongoing regulatory interactions and to update the Imfinzi label with these
important data.”

In May 2017, AstraZeneca Plc announced that the PACIFIC trial met its first primary
endpoint of PFS by demonstrating a median improvement of 11.2 months vs. placebo,
as assessed by blinded independent central review.

Imfinzi is currently approved in the US and Canada for the treatment of patients
with unresectable Stage III NSCLC who had not progressed following platinum-based
chemoradiation therapy and under regulatory review in the EU, Japan and other jurisdictions
with expected decisions in the second half of 2018.

Share on:
